logo-loader
viewMindMed Inc.

MindMed files patents for technologies to optimize and personalize psychedelic dosing regimens

Research by MindMed and its Swiss partner has identified new ways to predict and optimize both the amount of psychedelics needed and the dosing regimen required for therapy

MindMed Inc. -
The two patent applications cover MDMA dose optimization and LSD dose response

Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) told investors Wednesday that it is developing proprietary methods that will personalize psychedelic therapies for each patient.

The New York-based company, along with its Swiss partner the University Hospital Basel, has filed two separate patent applications for technologies that will screen and optimize the dosing of MDMA and LSD.

Research and development surrounding the technology is currently taking place at the University Hospital Basel’s Liechti Lab, which has identified new ways to predict and optimize both the amount of psychedelics needed and the dosing regimen required for therapy.

READ: MindMed to collaborate on study of DMT intravenous dosing regimens with Swiss research partner

"One size never fits all. Healing through psychedelics is a deeply personal process and we believe the personalization of psychedelic therapies is pivotal to the future of this fast growing field of medicine,” MindMed CEO JR Rahn said in a statement.

MindMed and Liechti Lab's analytics method aggregates multiple data and criteria of patients in a pre-dose screening and analysis process, the company told shareholders. The firm is hoping to use this approach to help treat patients who suffer from mental health or addiction disorders, it added.

“Through such analytics and dosing technologies we hope to give patients the best possible outcome from their therapy experiences,” Rahn added.

The approach includes dosing based on solid dose-response data, simple adjustments based on gender and body weight, and pharmacogenetic and personality predictors to optimize dosing to induces specific mental states, according to the technology’s co-founder Dr Matthias Liechti of the University Hospital Basel.

“MindMed has provided the long needed resources to ensure our Lab's inventions can be further developed and hopefully reach the market faster and safer than ever before,” Liechti said in a statement.

The two patent applications cover MDMA dose optimization and LSD dose response. In addition, MindMed has received the exclusive rights from the University Hospital Basel to commercialize the outcome of these patent applications on a global basis. 

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: MindMed Inc.

Price: 0.35942 USD

OTCQB:MMEDF
Market: OTCQB
Market Cap: $71.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MindMed Inc. named herein, including the promotion by the Company of MindMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MindMed takes another step forward adding MDMA to their R&D pipeline

MindMed (OTCQB: MMEDF) CO-CEO Jr Rahn joined Steve Darling from Proactive to announce the company has now added MDMA to its research and development pipeline. Rahn telling Proactive about some of the clinical studies they are doing including a new one called Project Lucy.

on 5/6/20

2 min read